Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits

Journal of Urology

Volumn 175, Issue 2, 2006, Pages 510-517

  Candas, Bernard ^a,c   Labrie, Fernand ^a,b,c   Gomez, José Luis ^a,b,c   Cusan, Leonello ^b,c   Chevrette, Éric ^b   Lévesque, Jacques ^b   Brousseau, Ghyslain ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Department of Medicine ^*  (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 30344442176     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00165-5     Document Type: Article

References (20)

1. B. Candas, L. Cusan, J.L. Gomez, P. Diamond, R.E. Suburu, J. Levesque Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer Prostate 45 2000 19
2. F. Labrie, A. Dupont, R. Suburu, L. Cusan, J.L. Gomez, M. Koutsilieris Optimized strategy for detection of early stage, curable prostate cancer role of prescreening with prostate-specific antigen Clin Invest Med 16 1993 425
3. J. Hugosson, G. Aus, H. Lilja, P. Lodding, C.G. Pihl, E. Pileblad Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable J Urol 169 2003 1720
4. T. Makinen, T.L. Tammela, M. Hakama, U.H. Stenman, S. Rannikko, J. Aro Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen Clin Cancer Res 9 2003 2435
5. F. Labrie, B. Candas, L. Cusan, J.L. Gomez, P. Diamond, R. Suburu Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen Urology 47 1996 212
6. T. Makinen, T.L. Tammela, U.H. Stenman, L. Maattanen, J. Aro, H. Juusela Second round results of the Finnish population-based prostate cancer screening trial Clin Cancer Res 10 2004 2231
7. R.F. Hoedemaeker, T.H. van der Kwast, R. Boer, H.J. de Koning, M. Roobol, A.N. Vis Pathologic features of prostate cancer found at population-based screening with a four-year interval J Natl Cancer Inst 93 2001 1153
8. H.J. de Koning, A. Auvinen, A. Berenguer Sanchez, F. Calais da Silva, S. Ciatto, L. Denis Large-scale randomized prostate cancer screening trials program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial Int J Cancer 97 2002 237
9. I.W. van der Cruijsen-Koeter, T.H. van der Kwast, F.H. Schroder Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam J Natl Cancer Inst 95 2003 1462
10. K. Ito, T. Yamamoto, M. Ohi, H. Takechi, K. Kurokawa, K. Suzuki Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less Prostate 57 2003 8
11. K. Ito, T. Yamamoto, M. Ohi, H. Takechi, K. Kurokawa, K. Suzuki Natural history of PSA increase with and without prostate cancer Urology 62 2003 64
12. K. Ito, T. Yamamoto, M. Ohi, H. Takechi, K. Kurokawa, K. Suzuki Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer Int J Cancer 109 2004 455
13. D. Crawford, D. Chia, G.L. Andriole, D. Reding, E.P. Gelmann, J.K. Gohagan PSA testing interval, reduction in screen in intervals data from the prostate, lung, colorectal, and ovarian cancer (PLCO) screening trial J Urol 167 suppl 2001 99 abstract 397
14. J.K. Gohagan, P.C. Prorok, B.S. Kramer, J.E. Cornett Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute J Urol 152 1994 1905
15. K. Ito, T. Yamamoto, K. Suzuki, K. Kurokawa, H. Yamanaka The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less J Urol 171 2004 656
16. F. Labrie, B. Candas, L. Cusan, J.L. Gomez, A. Belanger, G. Brousseau Screening decreases prostate cancer mortality 11-year follow-up of the 1988 Quebec prospective randomized controlled trial Prostate 59 2004 311
17. F. Labrie, A. Dupont, R. Suburu, L. Cusan, M. Tremblay, J.L. Gomez Serum prostate specific antigen as pre-screening test for prostate cancer J Urol 147 1992 846
18. P. Gjengsto, O.J. Halvorsen, L.A. Akslen, J. Frugard, P.A. Hoisaeter Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded a prospective study of 510 patients Urology 62 2003 447
19. B. Djavan, A.R. Zlotta, M. Remzi, K. Ghawidel, B. Bursa, S. Hruby Total and transition zone prostate volume and age how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 54 1999 846
20. F.H. Schroder, M. Roobol-Bouts, A.N. Vis, T. van der Kwast, R. Kranse Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination Urology 57 2001 83